<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>Microsoft Word - M Pharm PCI Syllabus all branches</title><meta name="author" content="HP"/><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 .s1 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 10pt; }
 .s2 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s3 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .p, p { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; margin:0pt; }
 .a, a { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 9pt; }
 .s4 { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 9pt; }
 .s5 { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 li {display: block; }
 #l1 {padding-left: 0pt;counter-reset: c1 2; }
 #l1> li>*:first-child:before {counter-increment: c1; content: counter(c1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l1> li:first-child>*:first-child:before {counter-increment: c1 0;  }
 #l2 {padding-left: 0pt;counter-reset: c2 1; }
 #l2> li>*:first-child:before {counter-increment: c2; content: counter(c2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l2> li:first-child>*:first-child:before {counter-increment: c2 0;  }
 li {display: block; }
 #l3 {padding-left: 0pt;counter-reset: d1 2; }
 #l3> li>*:first-child:before {counter-increment: d1; content: counter(d1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l3> li:first-child>*:first-child:before {counter-increment: d1 0;  }
 #l4 {padding-left: 0pt;counter-reset: d2 1; }
 #l4> li>*:first-child:before {counter-increment: d2; content: counter(d2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l4> li:first-child>*:first-child:before {counter-increment: d2 0;  }
 li {display: block; }
 #l5 {padding-left: 0pt;counter-reset: e1 2; }
 #l5> li>*:first-child:before {counter-increment: e1; content: counter(e1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l5> li:first-child>*:first-child:before {counter-increment: e1 0;  }
 #l6 {padding-left: 0pt;counter-reset: e2 1; }
 #l6> li>*:first-child:before {counter-increment: e2; content: counter(e2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l6> li:first-child>*:first-child:before {counter-increment: e2 0;  }
 li {display: block; }
 #l7 {padding-left: 0pt;counter-reset: f1 1; }
 #l7> li>*:first-child:before {counter-increment: f1; content: counter(f1, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l7> li:first-child>*:first-child:before {counter-increment: f1 0;  }
 li {display: block; }
 #l8 {padding-left: 0pt;counter-reset: g1 1; }
 #l8> li>*:first-child:before {counter-increment: g1; content: counter(g1, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l8> li:first-child>*:first-child:before {counter-increment: g1 0;  }
 #l9 {padding-left: 0pt;counter-reset: g2 1; }
 #l9> li>*:first-child:before {counter-increment: g2; content: counter(g2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l9> li:first-child>*:first-child:before {counter-increment: g2 0;  }
 li {display: block; }
 #l10 {padding-left: 0pt;counter-reset: h1 2; }
 #l10> li>*:first-child:before {counter-increment: h1; content: counter(h1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l10> li:first-child>*:first-child:before {counter-increment: h1 0;  }
 #l11 {padding-left: 0pt;counter-reset: h2 1; }
 #l11> li>*:first-child:before {counter-increment: h2; content: counter(h2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l11> li:first-child>*:first-child:before {counter-increment: h2 0;  }
 li {display: block; }
 #l12 {padding-left: 0pt;counter-reset: i1 1; }
 #l12> li>*:first-child:before {counter-increment: i1; content: counter(i1, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l12> li:first-child>*:first-child:before {counter-increment: i1 0;  }
</style><link rel="sitemap" type="application/xml" title="Sitemap" href="/sitemap.xml"></head><body><div style="display:flex;justify-content:flex-end;"><a href="#" target="_blank" download="" id="pdf-download-link"><button type="button" style="cursor:pointer;-webkit-appearance:button;color:#fff;background-color:#007bff;border-color:#007bff;display:inline-block;font-weight:400;text-align:center;white-space:nowrap;vertical-align:middle;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;border:1px solid transparent;padding:0.375rem 0.75rem;font-size:1rem;line-height:1.5;border-radius:0.25rem;transition:color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;text-transform:none;overflow:visible;margin:0;font-family:inherit;" download>Download</button></a></div><script>const a=(window.location.pathname).split(/);const filename=a[a.length-1].replace(".html",".pdf").replace(".htm",".pdf");document.getElementById("pdf-download-link").href=filename;</script><p class="s1" style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">PHARMACEUTICAL REGULATORY AFFAIRS (MRA)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p class="s3" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">GOOD REGULATORY PRACTICES (MRA 101T)</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course is designed to impart fundamental knowledge on various Good Regulatory Practices viz., cGMP, GLP, GALP and GDP for Pharmaceuticals, Cosmetics, Food &amp; Nutraceuticals, Medical devices, <span class="s2">In-vitro </span>Diagnostic Medical Devices (IVDs) and biological products and understand the rationale behind these requirements and will propose ways and means of complying with them.</p><p class="s2" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 87%;text-align: justify;">At completion of this course it is expected that students will be able to understand,</p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: justify;"> <span class="p">The key regulatory and compliance elements with respect to Good Manufacturing Practices, Good Laboratory Practices, Good Automated Laboratory Practices and Good Documentation Practices.</span></p><p class="s2" style="padding-top: 3pt;padding-left: 41pt;text-indent: -18pt;line-height: 74%;text-align: justify;"> <span class="p">Prepare and implement the check lists and SOPs for various Good Regulatory Practices</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 89%;text-align: justify;"> <span class="p">Implement Good Regulatory Practices in the Healthcare and related Industries</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">  <span class="p">Prepare for the readiness and conduct of audits and inspections.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">THEORY                                 60 Hrs</p><p style="padding-top: 2pt;padding-left: 27pt;text-indent: -22pt;line-height: 89%;text-align: justify;">1.   <span class="s2">Current Good Manufacturing Practices: </span>Introduction, US cGMP Part 210 and Part 211.EC Principles of GMP (Directive 91/356/EEC) Article 6 to Article 14 and WHO cGMP guidelines GAMP-5; Medical device and IVDs Global Harmonization Task Force(GHTF) Guidance docs.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l1"><li data-list-text="2"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Good  Laboratory  Practices:  <span class="p">Introduction,  USFDA  GLP Regulations (Subpart A to Subpart K), Controlling the GLP inspection process, Documentation, Audit, goals of Laboratory Quality Audit, Audit tools, Future of GLP regulations, relevant ISO and Quality Council of India(QCI) Standards</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="3"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 83%;text-align: left;">Good Automated Laboratory Practices: <span class="p">Introduction to GALP, Principles of GALP, GALP Requirements, SOPs of GALP, Training Documentation,21 CFR Part 11, General check list of 21CFR Part 11, Software Evaluation checklist, relevant ISO and QCI Standards</span>.</p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p></li><li data-list-text="4"><p class="s2" style="padding-top: 3pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Good Distribution Practices<span class="p">: Introduction to GDP, Legal GDP requirements  put  worldwide,  Principles,  Personnel, Documentation, Premises and Equipment, Deliveries to Customers, Returns, Self-Inspection, Provision of information, Stability testing principles, WHO GDP, USP GDP (Supply chain integrity), relevant CDSCO guidance and ISO standards</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="5"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Quality management systems: <span class="p">Concept of Quality, Total Quality Management, Quality by design, Six Sigma concept, Out of Specifications (OOS), Change control. Validation: Types of Validation, Types of Qualification, Validation master plan (VMP), Analytical Method Validation. Validation of utilities, [Compressed air, steam, water systems, Heat Ventilation and Air conditioning (HVAC)]and Cleaning Validation. The International Conference on Harmonization (ICH) process, ICH guidelines to establish quality, safety and efficacy of drug substances and products, ISO 13485, Sch MIII and other relevant CDSCO regulatory guidance documents.</span></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><ol id="l2"><li data-list-text="1."><p style="padding-top: 6pt;padding-left: 26pt;text-indent: -14pt;line-height: 74%;text-align: left;">Good Laboratory Practice Regulations, by Sandy Weinberg, Fourth Edition Drugs and the Pharmaceutical Sciences, Vol.168</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Good Pharmaceutical Manufacturing practice, Rational and compliance by John Sharp, CRC Press</p></li><li data-list-text="3."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Establishing a cGMP Laboratory Audit System, A practical Guide by David M.Bleisner, Wiley Publication.</p></li><li data-list-text="4."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: left;">How to practice GLP by PP Sharma, Vandana Publications.</p></li><li data-list-text="5."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 87%;text-align: left;">Laboratory Auditing for Quality and Regulatory compliance bu Donald C.Singer, Drugs and the Pharmaceutical Sciences, Vol.150.</p></li><li data-list-text="6."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 12pt;text-align: left;">Drugs &amp; Cosmetics Act, Rules &amp; Amendments</p></li></ol></li></ol><p class="s3" style="padding-top: 3pt;padding-left: 52pt;text-indent: 0pt;line-height: 113%;text-align: center;">DOCUMENTATION AND REGULATORY WRITING (MRA 102T)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 3pt;padding-left: 7pt;text-indent: 0pt;line-height: 88%;text-align: left;">This course is designed to impart fundamental knowledge on documentation and general principles involved in regulatory writing and submission to agencies.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Upon completion of the course the student shall be able to,</p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 87%;text-align: left;">  <span class="p">Know the various documents pertaining to drugs in pharmaceutical industry</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  <span class="p">Understand the basics of regulatory compilation</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">Create and assemble the regulation submission as per the requirements of agencies</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  <span class="p">Follow up the submissions and post approval document requirements</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 12pt;text-indent: 0pt;text-align: center;">THEORY                                 60 Hrs</p><p style="padding-top: 4pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">1.  <span class="s2">Documentation  in  pharmaceutical  industry</span>:  Exploratory Product Development Brief (EPDB) for Drug substance and Drug product, Product Development Plan (PDP), Product Development Report (PDR), Master Formula Record, Batch Manufacturing Record and its calculations, Batch Reconciliation, Batch Packaging Records, Print pack specifications, Distribution records, Certificate of Analysis (CoA), Site Master File and Drug Master Files (DMF).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l3"><li data-list-text="2"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Dossier  preparation  and  submission:  <span class="p">Introduction  and overview of dossiers, contents and organization of dossier, binders and sections, compilation and review of dossier. Paper submissions, overview and modules of CTD, electronic CTD submissions; Electronic submission: Planning electronic submission, requirements for submission, regulatory bindings and requirements, Tool and Technologies, electronic dossier submission process and validating the submission, Electronic Submission Gateway (ESG). Non eCTD electronic submissions (NeeS), Asian CTD formats (ACTD) submission. Organizing, process and validation of submission. Submission in Sugam system of CDSCO.</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p></li><li data-list-text="3"><p class="s2" style="padding-top: 3pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Audits: <span class="p">Introduction, Definition, Summary, Types of audits, GMP compliance audit, Audit policy, Internal and External Audits, Second Party Audits, External third party audits, Auditing strategies, Preparation and conducting audit, Auditing strategies, audit analysis, audit report, audit follow up. Auditing/inspection of manufacturing facilities by regulatory agencies. Timelines for audits/inspection. GHTF study group 4 guidance document. ISO 13485.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="4"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Inspections:  <span class="p">Pre-approval  inspections,  Inspection  of pharmaceutical manufacturers, Inspection of drug distribution channels, Quality systems requirements for national good manufacturing practice inspectorates, inspection report, model certificate of good manufacturing practices, Root cause analysis, Corrective and Preventive action (CAPA).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="5"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Product life cycle management: <span class="p">Prior Approval Supplement (PAS), Post Approval Changes [SUPAC], Changes Being Effected in 30 Days (CBE-30), Annual Report, Post marketing Reporting Requirements, Post approval Labeling Changes, Lifecycle Management, FDA Inspection and Enforcement, Establishment Inspection Report (EIR), Warning Letters, Recalls, Seizure and Injunctions. ISO Risk Management Standard</span></p><p class="s2" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><ol id="l4"><li data-list-text="1."><p style="padding-top: 3pt;padding-left: 41pt;text-indent: -21pt;line-height: 86%;text-align: justify;">Compliance auditing for Pharmaceutical Manufacturers. Karen Ginsbury and Gil Bismuth, Interpharm/CRC, Boca Raton, London New York, Washington D.C.</p></li><li data-list-text="2."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 86%;text-align: justify;">Pharmaceutical Manufacturing Handbook, Regulations and Quality by Shayne Cox Gad. Wiley-Interscience, A John Wiley and sons, Inc., Publications.</p></li><li data-list-text="3."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 86%;text-align: justify;">Handbook of microbiological Quality control. Rosamund M. Baird, Norman A. Hodges, Stephen P. Denyar. CRC Press. 2000.</p></li><li data-list-text="4."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 85%;text-align: justify;">Laboratory auditing for quality and regulatory compliance. Donald C. Singer, Raluca-loana Stefan, Jacobus F. Van Staden. Taylor and Francis (2005).</p></li><li data-list-text="5."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 85%;text-align: justify;">Implementing Juran&#39;s Road Map for Quality Leadership: Benchmarks and Results, By Al Endres, Wiley, 2000</p></li><li data-list-text="6."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 83%;text-align: justify;">Understanding, Managing and Implementing Quality: Frameworks, Techniques and Cases, By Jiju Antony; David Preece, Routledge, 2002</p></li><li data-list-text="7."><p class="s2" style="padding-top: 2pt;padding-left: 41pt;text-indent: -21pt;line-height: 86%;text-align: justify;">	<span class="p">Organizing for High Performance: Employee Involvement, TQM, Reengineering, and Knowledge Management in the Fortune 1000: The CEO Report By Edward E. Lawler; Susan Albers Mohrman; George Benson, Jossey-Bass, 2001</span></p></li><li data-list-text="8."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 86%;text-align: justify;">Corporate Culture and the Quality Organization By James W. Fairfield- Sonn, Quorum Books, 2001</p></li><li data-list-text="9."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 85%;text-align: justify;">The Quality Management Sourcebook: An International Guide to Materials and Resources By Christine Avery; Diane Zabel, Routledge, 1997</p></li><li data-list-text="10."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 85%;text-align: justify;">The Quality Toolbox, Second Edition, Nancy R. Tague, ASQ Publications</p></li><li data-list-text="11."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 11pt;text-align: justify;">Juran&#39;s Quality Handbook, Sixth Edition, Joseph M. Juran and Joseph</p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 13pt;text-align: left;">A. De Feo, ASQ Publications</p></li><li data-list-text="12."><p style="padding-top: 1pt;padding-left: 41pt;text-indent: -21pt;line-height: 85%;text-align: justify;">Root Cause Analysis, The Core of Problem Solving and Corrective Action, Duke Okes, 2009, ASQ Publications</p></li><li data-list-text="13."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 84%;text-align: justify;">International Medical Device Regulators Forum (IMDRF) Medical Device Single Audit Program (MDSAP)</p></li></ol></li></ol><p class="s3" style="padding-top: 3pt;padding-left: 138pt;text-indent: -63pt;line-height: 113%;text-align: left;">CLINICAL RESEARCH REGULATIONS (MRA 103T)</p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course is designed to impart the fundamental knowledge on the clinical development process of drugs, pharmaceuticals and Medical Devices, phases and conduct of clinical trials and research, regulations and guidance governing the conduct of clinical research in India, USA and EU. It prepares the students to learn in detail on various laws, legislations and guidance related to safety, efficacy, ethical conduct and regulatory approval of clinical research.</p><p class="s2" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: left;">Upon completion of the course, the student shall be able to (know, do and appreciate)</p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">History, origin and ethics of clinical and biomedical research and evaluation</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">Clinical drug, medical device development process and different types and phases of clinical trials</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">Regulatory requirements and guidance for conduct of clinical trials and research</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Theory                                  60 Hrs</p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">1.  <span class="s2">Clinical Drug Development Process</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">Different types of Clinical Studies</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">Phases of clinical trials, Clinical Trial protocol</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Phase 0 studies</span></p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 87%;text-align: justify;"> <span class="p">Phase I and subtype studies (single ascending, multiple ascending, dose escalation, methods, food effect studies, drug – drug interaction, PK end points</span></p><p class="s2" style="padding-top: 2pt;padding-left: 45pt;text-indent: -18pt;line-height: 86%;text-align: justify;"> <span class="p">Phase II studies (proof of concept or principle studies to establish efficacy)</span></p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 90%;text-align: justify;"> <span class="p">Phase III studies (Multi ethnicity, global clinical trial, registration studies)</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">  <span class="p">Phase IV studies (Post Marketing Studies; PSUR)</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Clinical Investigation and Evaluation of Medical Devices &amp;</p><p class="s2" style="padding-top: 1pt;padding-left: 27pt;text-indent: 0pt;text-align: left;">IVDs</p><p style="padding-top: 2pt;padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Different Types of Studies</p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 84%;text-align: left;">Key Concepts of Medical Device Clinical Evaluation Key concepts of Clinical Investigation</p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><ol id="l5"><li data-list-text="2"><p class="s2" style="padding-top: 1pt;padding-left: 27pt;text-indent: -22pt;line-height: 13pt;text-align: left;">Ethics in Clinical Research:</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">Historical Perspectives: Nuremberg Code, Thalidomide study</span></p><p style="padding-left: 45pt;text-indent: 0pt;line-height: 87%;text-align: left;">, Nazis Trials, Tuskegee Syphilis Study, The Belmont Report, The declaration of Helsinki</p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">Origin of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines.</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">The ethics of randomized clinical trials</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">The role of placebo in clinical trials</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Ethics of clinical research in special population</span></p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 87%;text-align: justify;">  <span class="p">Institutional  Review  Board/Independent  Ethics Committee/Ethics  Committee  –  composition,  roles, responsibilities, review and approval process and ongoing monitoring of safety data</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">  <span class="p">Data safety monitoring boards.</span></p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 88%;text-align: justify;"> <span class="p">Responsibilities of sponsor, CRO, and investigator in ethical conduct of clinical research</span></p><p class="s2" style="padding-left: 45pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">Ethical principles governing informed consent process</span></p><p class="s2" style="padding-left: 45pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Patient Information Sheet and Informed Consent Form</span></p><p class="s2" style="padding-left: 45pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">The informed consent process and documentation</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="3"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 13pt;text-align: left;">Regulations governing Clinical Trials</p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 87%;text-align: justify;">India: <span class="p">Clinical Research regulations in India – Schedule Y &amp; Medical Device Guidance</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">USA: <span class="p">Regulations to conduct drug studies in USA (FDA)</span></p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 90%;text-align: justify;"> <span class="p">NDA 505(b)(1) of the FD&amp;C Act (Application for approval of a new drug)</span></p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 86%;text-align: justify;"> <span class="p">NDA 505(b)(2) of the FD&amp;C Act (Application for approval of a new drug that relies, at least in part, on data not developed by the applicant)</span></p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 87%;text-align: justify;"> <span class="p">ANDA 505(j) of the FD&amp;C Act (Application for approval of a generic drug product)</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">  <span class="p">FDA Guidance for Industry - Acceptance of Foreign Clinical</span></p><p style="padding-left: 45pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Studies</p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">FDA Clinical Trials Guidance Document: Good Clinical Practice</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">EU: <span class="p">Clinical Research regulations in European Union (EMA)</span></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p></li><li data-list-text="4"><p class="s2" style="padding-top: 1pt;padding-left: 28pt;text-indent: -22pt;line-height: 13pt;text-align: left;">Clinical Research Related Guidelines</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">Good Clinical Practice Guidelines (ICH GCP E6)</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">Indian GCP Guidelines</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">ICMR Ethical Guidelines for Biomedical Research</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">CDSCO guidelines</span></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">GHTF study group 5 guidance documents</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Regulatory Guidance on Efficacy and Safety ICH Guidance’s</p><p class="s2" style="padding-top: 6pt;padding-left: 46pt;text-indent: -18pt;line-height: 77%;text-align: left;">  <span class="p">E4 – Dose Response Information to support Drug Registration</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">E7 – Studies in support of General Population: Geriatrics</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">E8 – General Considerations of Clinical Trials</span></p><p class="s2" style="padding-left: 46pt;text-indent: -18pt;line-height: 89%;text-align: left;">  <span class="p">E10 – Choice of Control Groups and Related Issues in Clinical Trials,</span></p><p class="s2" style="padding-left: 45pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">E 11 – Clinical Investigation of Medicinal Products in the Pediatric Population</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  <span class="p">General biostatics principle applied in clinical research</span></p></li><li data-list-text="5"><p class="s2" style="padding-top: 1pt;padding-left: 27pt;text-indent: -22pt;line-height: 67%;text-align: left;">USA &amp; EU Guidance USA: FDA Guidance</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">CFR 21Part 50: Protection of Human Subjects</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  <span class="p">CFR 21Part 54: Financial Disclosure by Clinical Investigators</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  <span class="p">CFR 21Part 312: IND Application</span></p><p class="s2" style="padding-top: 1pt;padding-left: 27pt;text-indent: 0pt;line-height: 78%;text-align: left;">  <span class="p">CFR 21Part 314: Application for FDA Approval to Market a New Drug</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 78%;text-align: left;">  <span class="p">CFR  21Part 320: Bioavailability and bioequivalence requirements</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">  <span class="p">CFR 21Part 812: Investigational Device Exemptions</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  <span class="p">CFR 21Part 822: Post-market surveillance</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 79%;text-align: left;">  <span class="p">FDA Safety Reporting Requirements for INDs and BA/BE Studies</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">  <span class="p">FDA Med Watch</span></p><p class="s2" style="padding-top: 1pt;padding-left: 27pt;text-indent: 0pt;line-height: 77%;text-align: left;">  <span class="p">Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 8pt;text-align: left;">European Union: EMA Guidance</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">EU Directives 2001</span></p><p class="s2" style="padding-top: 1pt;padding-left: 45pt;text-indent: -18pt;line-height: 80%;text-align: left;">  <span class="p">EudraLex (EMEA) Volume 3 – Scientific guidelines for medicinal products for human use</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">  <span class="p">EU Annual Safety Report (ASR)</span></p><p class="s2" style="padding-top: 1pt;padding-left: 45pt;text-indent: -18pt;line-height: 78%;text-align: left;">  <span class="p">Volume 9A – Pharmacovigilance for Medicinal Products for Human Use</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 10pt;text-align: left;">  <span class="p">EU MDD with respect to clinical research</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">ISO 14155</span></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p class="s2" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><ol id="l6"><li data-list-text="1."><p style="padding-top: 4pt;padding-left: 41pt;text-indent: -21pt;line-height: 76%;text-align: justify;">Clinical Trials and Human Research: A Practical Guide to Regulatory Compliance By Fay A. Rozovsky and Rodney K. Adams</p></li><li data-list-text="2."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 75%;text-align: justify;">HIPAA and Human Subjects Research: A Question and Answer Reference Guide By Mark Barnes, JD, LLM and Jennifer Kulynych, JD, PhD</p></li><li data-list-text="3."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 75%;text-align: justify;">Principles and Practices of Clinical Research, Second Edition Edited by John I. Gallin and Frederick P. Ognibene</p></li><li data-list-text="4."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 75%;text-align: justify;">Reviewing Clinical Trials: A Guide for the Ethics Committee; Johan PE Karlberg and Marjorie A Speers; Karlberg, Johan Petter Einar, Hong Kong.</p></li><li data-list-text="5."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 75%;text-align: justify;">International Pharmaceutical Product Registration: Aspects of Quality, Safety and Efficacy; Anthony C. Cartwright; Taylor &amp; Francis Inc., USA.</p></li><li data-list-text="6."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 74%;text-align: justify;">New Drug Approval Process: The Global Challenge; Guarino, Richard A; Marcel Dekker Inc., NY.</p></li><li data-list-text="7."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 75%;text-align: justify;">FDA regulatory affairs: a guide for prescription drugs, medical devices, and biologics; Douglas J. Pisano, David Mantus; CRC Press, USA</p></li><li data-list-text="8."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 9pt;text-align: justify;">Country Specific Guidelines from official websites.</p></li><li data-list-text="9."><p style="padding-left: 41pt;text-indent: -21pt;line-height: 13pt;text-align: justify;">Drugs &amp; Cosmetics Act &amp; Rules and Amendments</p></li></ol></li></ol><p class="s2" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;line-height: 10pt;text-align: left;">RECOMMENDED WEBSITES:</p><ol id="l7"><li data-list-text="1."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 12pt;text-align: left;"><a href="http://www.eortc.be/services/doc" class="s5" target="_blank">EU Clinical Research Directive 2001: </a><a href="http://www.eortc.be/services/doc" target="_blank">http://www.eortc.be/services/doc</a></p><p class="s4" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">/clinical-eudirective-04-april-01.<span class="p">pdf</span></p></li><li data-list-text="2."><p style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 75%;text-align: left;"><a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm" class="s5" target="_blank">Code    of   Federal    Regulations,   FDA: </a><a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm" target="_blank">http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm</a></p></li><li data-list-text="3."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 73%;text-align: left;"><a href="http://www/" class="s5" target="_blank">Guidelines of International Conference on Harmonization: </a><a href="http://www/" class="a" target="_blank">http://www</a>. i<u>ch.org/products/guidelines.htm</u>l</p></li><li data-list-text="4."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 9pt;text-align: left;"><a href="http://www.gmpcompliance.info/euguide.htm" class="s5" target="_blank">Eudralex Guidelines: </a><a href="http://www.gmpcompliance.info/euguide.htm" target="_blank">http://www.gmpcompliance.info/euguide.htm</a></p></li><li data-list-text="5."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">FDA New Drug Application:</p></li><li data-list-text="6."><p class="s4" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 73%;text-align: left;">http://www.fda.gov/regulatoryinformation/legislation/FederalFoodDruga<span class="p"> </span>ndCosmetic</p><p class="s4" style="padding-left: 41pt;text-indent: 0pt;line-height: 9pt;text-align: left;">ActFDCAct/FDCActChapterVDrugsandDevices/ucm108125.htm</p></li><li data-list-text="7."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 10pt;text-align: left;"><a href="http://www/" class="s5" target="_blank">Medicines and Healthcare products Regulatory Agency: </a><a href="http://www/" target="_blank">http://www</a></p><p class="s4" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">.mhra.gov.u<span class="p">k</span></p></li><li data-list-text="8."><p style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 75%;text-align: left;"><a href="http://cdsco.nic.in/CDSCO-GuidanceForIndustry.pdf" class="s5" target="_blank">Central Drugs Standard Control Organization Guidance for Industry: </a><a href="http://cdsco.nic.in/CDSCO-GuidanceForIndustry.pdf" class="a" target="_blank">http://cdsco.nic.in/CDSCO-GuidanceForIndustry.pd</a><a href="http://cdsco.nic.in/CDSCO-GuidanceForIndustry.pdf" class="s5" target="_blank">f</a></p></li><li data-list-text="9."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 9pt;text-align: left;"><a href="http://icmr.nic.in/" class="s5" target="_blank">ICMR Ethical Guidelines for Biomedical Research: </a><a href="http://icmr.nic.in/" target="_blank">http://icmr.nic.in</a></p></li></ol><p class="s4" style="padding-left: 41pt;text-indent: 0pt;line-height: 13pt;text-align: left;">/ethical_guidelines.pdf</p><p class="s3" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 113%;text-align: center;">REGULATIONS AND LEGISLATION FOR DRUGS &amp; COSMETICS, MEDICAL DEVICES, BIOLOGICALS &amp; HERBALS, AND FOOD &amp; NUTRACEUTICALS IN INDIA AND INTELLECTUAL PROPERTY RIGHTS</p><p class="s3" style="padding-left: 52pt;text-indent: 0pt;text-align: center;">(MRA 104T)</p><p class="s2" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course is designed to impart fundamental knowledge on regulations and legislation in India w.r.t. Drugs &amp; Cosmetics, Medical Devices, Biologicals &amp; Herbals, and Food &amp; Nutraceuticals. It prepares the students for basic regulatory requirements in India of Drugs &amp; Cosmetics, Medical Devices, Biologicals &amp; Herbals, and Food &amp; Nutraceuticals. for manufacture, import &amp; registration, export, sale, marketing authorization, clinical trials and intellectual property rights.</p><p class="s2" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: justify;">Upon the completion of the course the student shall be able to:</p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: justify;"> <span class="p">Know different Acts and guidelines that regulate Drugs &amp; Cosmetics, Medical Devices, Biologicals &amp; Herbals, and Food &amp; Nutraceuticals industry in India.</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">  <span class="p">Understand the approval process and regulatory requirements for</span></p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 86%;text-align: justify;">Drugs &amp; Cosmetics, Medical Devices, Biologicals &amp; Herbals, and Food &amp; Nutraceuticals</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">THEORY                                60 Hrs</p><ol id="l8"><li data-list-text="1."><p class="s2" style="padding-top: 5pt;padding-left: 27pt;text-indent: -22pt;line-height: 68%;text-align: left;">Biologicals &amp; Herbals, and Food &amp; Nutraceuticals Acts and Rules (with latest amendments):</p><ol id="l9"><li data-list-text="1."><p style="padding-top: 7pt;padding-left: 63pt;text-indent: -18pt;line-height: 73%;text-align: justify;">Drugs and Cosmetics Act 1940 and Rules 1945: DPCO and NPPA</p></li><li data-list-text="2."><p style="padding-left: 63pt;text-indent: -18pt;line-height: 86%;text-align: justify;">Other relevant provisions (rules schedules and guidelines for approval of Drugs &amp; Cosmetics, Medical Devices, Biologicals &amp; Herbals, and Food &amp; Nutraceuticals in India</p></li></ol></li></ol><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: justify;">Other relevant Acts: <span class="p">Narcotics Drugs and Psychotropic Substances Act; Medicinal and Toilet Preparations (Excise Duties) Act, 1955; Pharmacy Act, 1948; Drugs and Magic Remedies (Objectionable Advertisements) Act, 1955; Prevention of Cruelty to Animals Act.</span></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><ol id="l10"><li data-list-text="2"><p class="s2" style="padding-top: 5pt;padding-left: 27pt;text-indent: -22pt;line-height: 67%;text-align: justify;">Regulatory requirements and approval procedures for Drugs &amp; Cosmetics Medical Devices, Biologicals &amp; Herbals, and</p><p class="s2" style="padding-top: 1pt;padding-left: 27pt;text-indent: 0pt;text-align: left;">Food &amp; Nutraceuticals</p><p style="padding-top: 6pt;padding-left: 27pt;text-indent: 0pt;line-height: 73%;text-align: justify;">CDSCO (Central Drug Standard Control Organization) and State Licensing Authority: Organization, Responsibilities</p><p class="s2" style="padding-left: 63pt;text-indent: -18pt;line-height: 87%;text-align: justify;"> <span class="p">Rules, regulations, guidelines and standards for regulatory filing of Drugs &amp; Cosmetics, Medical Devices, Biologicals &amp; Herbals, and Food &amp; Nutraceuticals</span></p><p class="s2" style="padding-left: 27pt;text-indent: 18pt;line-height: 86%;text-align: justify;"> <span class="p">Format and contents of Regulatory dossier filing Clinical trial/ investigations</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="3"><p style="padding-left: 27pt;text-indent: -22pt;line-height: 87%;text-align: justify;">Indian Pharmacopoeial Standards, BIS standards and ISO and other relevant standards</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="4"><p style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Bioavailability and Bioequivalence data (BA &amp;BE), BCS Classification  of  Drugs,  Regulatory  Requirements  for Bioequivalence study</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Stability requirements: <span class="p">ICH and WHO</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;text-align: left;">Guidelines for Drug testing in animals/<span class="p">Preclinical Studies</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: left;">Animal testing: Rationale for conducting studies, CPCSEA Guidelines</p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: left;">Ethical guidelines for human participants ICMR- DBT Guidelines for Stem Cell Research</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="5"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 88%;text-align: justify;">Intellectual Property Rights<span class="p">: Patent, Trademark, Copyright, Industrial Designs and Geographical Indications, Indian Patent Scenario. IPR vs Regulatory Affairs</span></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p class="s2" style="padding-top: 8pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><ol id="l11"><li data-list-text="1."><p style="padding-top: 3pt;padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Manual of Patent Practice &amp; Procedure, 3rd Edition, by The Patent Office of India</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 87%;text-align: left;">Patent Failure How Judges, Bureaucrats, and Lawyers put innovators at risk by James Bessen and Michael J. Meurer</p></li><li data-list-text="3."><p style="padding-left: 26pt;text-indent: -13pt;line-height: 83%;text-align: left;">Principles and Practice of Clinical Trial Medicine by Richard Chin and Bruce Y. Lee</p></li><li data-list-text="4."><p style="padding-left: 26pt;text-indent: -13pt;line-height: 85%;text-align: left;">Ethical Guidelines for Biomedical Research on Human Participants by Indian Council of Medical Research New delhi 2006.</p></li><li data-list-text="5."><p style="padding-left: 28pt;text-indent: -14pt;line-height: 86%;text-align: left;">CPCSEA Guidelines for Laboratory Animal Facility by Committee for the purpose of control and supervision on experiments on animals (CPCSEA)</p></li><li data-list-text="6."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 13pt;text-align: justify;">ICH E6 Guideline ― Good Clinical Practice‖ by ICH Harmonised Tripartite</p></li><li data-list-text="7."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: justify;">Guidance for Industry on Submission of Clinical Trial Application for Evaluating Safety and Efficacy by CDSCO (Central Drug Standard Control Organisation)</p></li><li data-list-text="8."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: justify;">Guidance for Industry on Requirement of Chemical &amp; Pharmaceutical Information including Stability Study Data before approval of clinical trials / BE studies by CDSCO</p></li><li data-list-text="9."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: justify;">Guidelines for Import and Manufacture of Medical Devices by CDSCO</p></li><li data-list-text="10."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 13pt;text-align: left;">Guidelines from official website of CDSCO</p></li></ol></li></ol><p class="s3" style="padding-top: 3pt;padding-left: 141pt;text-indent: -66pt;line-height: 113%;text-align: left;">REGULATORY AFFAIRS PRACTICAL - I (MRA 105P)</p><ol id="l12"><li data-list-text="1."><p style="padding-left: 23pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Case studies (4 Nos.) of each of Good Pharmaceutical Practices.</p></li><li data-list-text="2."><p style="padding-top: 1pt;padding-left: 23pt;text-indent: -18pt;line-height: 85%;text-align: left;">Documentation for in process and finished products Quality control tests for Solid, liquid, Semisolid and Sterile preparations.</p></li><li data-list-text="3."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 11pt;text-align: left;">Preparation of SOPs, Analytical reports (Stability and validation)</p></li><li data-list-text="4."><p style="padding-left: 23pt;text-indent: -18pt;line-height: 86%;text-align: left;">Protocol preparation for documentation of various types of records (BMR, MFR, DR)</p></li><li data-list-text="5."><p style="padding-left: 23pt;text-indent: -18pt;line-height: 10pt;text-align: left;">Labeling comparison between brand &amp; generics.</p></li><li data-list-text="6."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of clinical trial protocol for registering trial in India</p></li><li data-list-text="7."><p style="padding-left: 23pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Registration for conducting BA/ BE studies in India</p></li><li data-list-text="8."><p style="padding-left: 23pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Import of drugs for research and developmental activities</p></li><li data-list-text="9."><p style="padding-left: 23pt;text-indent: -18pt;line-height: 86%;text-align: left;">Preparation of regulatory dossier as per Indian CTD format and submission in SUGAM</p></li><li data-list-text="10."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 11pt;text-align: left;">Registering for different Intellectual Property Rights in India</p></li><li data-list-text="11."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">GMP Audit Requirements as per CDSCO</p></li><li data-list-text="12."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation and documentation for Indian Patent application.</p></li><li data-list-text="13."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of checklist for registration of IND as per ICH CTD format.</p></li><li data-list-text="14."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of checklist for registration of NDA as per ICH CTD format.</p></li><li data-list-text="15."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of checklist for registration of ANDA as per ICH CTD format.</p></li><li data-list-text="16."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Case studies on response with scientific rationale to USFDA Warning Letter</p></li><li data-list-text="17."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of submission checklist of IMPD for EU submission.</p></li><li data-list-text="18."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Comparison study of marketing authorization procedures in EU.</p></li><li data-list-text="19."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Comparative study of DMF system in US, EU and Japan</p></li><li data-list-text="20."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of regulatory submission using eCTD software</p></li><li data-list-text="21."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of Clinical Trial Application (CTA) for US submission</p></li><li data-list-text="22."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of Clinical Trial Application (CTA) for EU submission</p></li><li data-list-text="23."><p style="padding-top: 1pt;padding-left: 23pt;text-indent: -18pt;line-height: 85%;text-align: left;">Comparison of Clinical Trial Application requirements of US, EU and Japan of a dosage form.</p></li><li data-list-text="24."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 11pt;text-align: left;">Regulatory requirements checklist for conducting clinical trials in India.</p></li><li data-list-text="25."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Regulatory requirements checklist for conducting clinical trials in Europe.</p></li><li data-list-text="26."><p style="padding-left: 23pt;text-indent: -17pt;line-height: 13pt;text-align: left;">Regulatory requirements checklist for conducting clinical trials in USA</p></li></ol></body></html>
